Abstract
Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Current Drug Targets
Title:Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Volume: 16 Issue: 8
Author(s): Zoltan V. Varga, Zoltan Giricz, Peter Bencsik, Rosalinda Madonna, Mariann Gyongyosi, Rainer Schulz, Manuel Mayr, Thomas Thum, Laszlo G. Puskas and Peter Ferdinandy
Affiliation:
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Abstract: Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Export Options
About this article
Cite this article as:
Varga V. Zoltan, Giricz Zoltan, Bencsik Peter, Madonna Rosalinda, Gyongyosi Mariann, Schulz Rainer, Mayr Manuel, Thum Thomas, Puskas G. Laszlo and Ferdinandy Peter, Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150427154203
DOI https://dx.doi.org/10.2174/1389450116666150427154203 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research Can Dietary Polyphenols Prevent the Formation of Toxic Compounds from Maillard Reaction?
Current Drug Metabolism Phenolic Compounds as Antioxidants: Carbonic Anhydrase Isoenzymes Inhibitors
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design The Yin and Yang of Inflammation
Current Molecular Medicine Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Genetic and Environmental Influences on Therapeutic and Toxicity Outcomes: Studies with CYP2A6
Current Clinical Pharmacology Novel Ligands: Fine Tuning the Transcriptional Activity of the Glucocorticoid Receptor
Current Pharmaceutical Design Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]
Current Pharmaceutical Design Nitrogen and Sulfur Co-doped Fluorescent Carbon Dots for the Detection of Morin and Cell Imaging
Current Analytical Chemistry Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews